References

1. Schwartzman S, Ruderman EM. A road map of the axial spondyloarthritis continuum. Mayo Clinic Proceed 2022;97(1):134-145. https://doi.org/10.1016/j.mayocp.2021.08.007
2. Slimani S, Hamdi W, Nassar K, Kalla AA. Spondyloarthritis in North Africa: An update. Clin Rheumatol 2021;40:3401-3410. https://doi.org/10.1007/s10067-021-05630-w
3. Tikly M, Njobvu P, McGill P. Spondyloarthritis in sub-Saharan Africa. Curr Rheumatol Rep 2014;16:421. https://doi.org/10.1007/s10067-021-05630-w 10.1007/s11926-014-0421-z
4. Sheehan NJ. The ramifications of HLA-B27. J Royal Soc Med 2004;97(1):10-14.
5. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology 2014;53(4):650-657.
6. Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: A systematic review. Rheumatol Ther 2020;7(1):65-87. https://doi.org/10.1007/s40744-020-00194-8.
7. Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum 2015;44(5):556-562. https://doi.org/10.1016/j.semarthrit.2014.10.009
8. Ward MM. Quality of life in patients with ankylosing spondylitis. Rheumatic Dis Clin North Am 1998;24(4):815-827.
9. Martindale J, Shukla R, Goodacre J. The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity. Best Pract Res Clin Rheumatol 2015;29(3):512-523. https://doi.org/10.1016/j.berh.2015.04.002
10. Landewé RB. Overdiagnosis and overtreatment in rheumatology: A little caution is in order. Ann Rheumat Dis 2018;77(10):1394-1396. https://doi.org/10.1136/annrheumdis-2018-213700
11. Bittar M, Khan MA, Magrey M. Axial spondyloarthritis and diagnostic challenges: Over-diagnosis, misdiagnosis, and under-diagnosis. Curr Rheumatol Rep 2023;25(3):47-55. https://doi.org/10.1007/ s11926-022-01096-0
12. Poddubnyy D, van Tubergen A, Landewé R, Sieper J, van der Heijde D. Development of an ASASendorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheumat Dis 2015;74(8):1483-1487.
13. Ozgocmen S, Akgul O, Khan MA. Mnemonic for assessment of the spondyloarthritis international society criteria. J Rheumatol 2010;37(9):1978. https://doi.org/10.3899/jrheum.100477
14. Mathieu A, Paladini F, Vacca A, Cauli A, Fiorillo MT, Sorrentino R. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmunity Rev 2009;8(5):420-425.
15. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheumat Dis 2009;68(6):777-783.
16. Sepriano A, Rubio R, Ramiro S, Landewé R, van der Heijde D. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: A systematic literature review and meta-analysis. Ann Rheumat Dis 2017;76(5):886-890.
17. Sepriano A, Ramiro S, van der Heijde D, et  al. What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. Ann Rheumat Dis 2020;79(3):324-331.
18. Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheumat Dis 2021;80(12):1511-1521.
19. Rudwaleit M. Fibromyalgia is not axial spondyloarthritis. Rheumatology 2018;57(9):1510-1512. https://doi.org/10.1093/rheumatology/kex372
20. Campos-Correia D, Sudoł-Szopińska I, Afonso D. Are we overcalling sacroiliitis on MRI? Differential diagnosis that every rheumatologist should know-Part I. Acta Reumatologica Portuguesa 2019;44(1):29-41.
21. Van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheumat Dis 2009;68(12):1811-1818.
22. Machado P, Landewé R, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS): Sefining cut-off values for disease activity states and improvement scores. Ann Rheumat Dis 2011;70(1):47-53. https://doi.org/10.1136/ard.2010.138594
23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21(12):2286-2291.
24. Cui R, Du Y, Tian N, Jiang H-L, Tao Y-L, Dai S-M. Equivalent cut-off values of Bath ankylosing spondylitis disease activity index corresponding to ankylosing spondylitis disease activity score cut-off values. Clin Exp Rheumatol 2023;41(5):1163-1169. https://doi.org/10.55563/clinexprheumatol/2kjgx2
25. Calin A, Garrett S, Whitelock H, et  al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath ankylosing spondylitis functional index. J Rheumatol 1994;21(12):2281-2285.
26. Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthr Rheumatism 1984;27(4):361-368.
27. Lambert RG, Bakker PA, van der Heijde D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: Update by the ASAS MRI working group. Ann Rheumat Dis 2016;75(11):1958-1563.
28. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheumat Dis 2014;73(8):1455-1461.
29. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheumat Dis 2009;68(6):863-867.
30. Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: Results from the GErman SPondyloarthritis Inception Cohort. Ann Rheumat Dis 2016;75(12):2114-2118.
31. Van der Heijde D, Joshi A, Pangan AL, et al. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology 2016;55(1):80-88.
32. Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis 2015;74(6):954-962.
33. Sudre A, Figuereido IT, Lukas C, Combe B, Morel J. On the impact of a dedicated educational program for ankylosing spondylitis: Effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. Joint Bone Spine 2011;79(1):99-100.
34. Candelas G, Villaverde V, García S, Guerra M, León M, Cañete J. Benefit of health education by a training nurse in patients with axial and/or peripheral psoriatic arthritis: A systematic literature review. Rheumatol Int 2016;36(11):1493-1506. https://doi.org/10.1007/s00296-016-3549-5
35. Dagfinrud H, Hagen KB, Kvien TK. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;(1):CD002822. https://doi.org/10.1002/14651858.CD002822.pub3
36. Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthritis: Unravelling the complexities. Rheumatology 2020;59(7):1472-1481. https://doi.org/10.1093/rheumatology/ keaa093
37. Roberts MJ, Leonard AN, Bishop NC, Moorthy A. Lifestyle modification and inflammation in people with axial spondyloarthropathy – a scoping review. Musculoskel Care 2022;20(3):516-528. https://doi. org/10.1002/msc.1625
38. Ortolan A, Webers C, Sepriano A, et al. Efficacy and safety of non-pharmacological and non-biological interventions: A systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheumat Dis 2023;82(1):142-152. https://doi.org/10.1136/ard-2022-223297
39. Osthoff A-KR, Niedermann K, Braun J, et  al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheumatic Dis 2018;77(9):1251-1260. https://doi.org/10.1136/annrheumdis-2018-213585
40. Noureldin B, Barkham N. The current standard of care and the unmet needs for axial spondyloarthritis. Rheumatology 2018;57(Suppl 6):vi10-vi17. https://doi.org/10.1093/rheumatology/key217
41. Hoving JL, Lacaille D, Urquhart DM, Hannu TJ, Sluiter JK, Frings‐Dresen MH. Non‐pharmacological interventions for preventing job loss in workers with inflammatory arthritis. Cochrane Database Syst Rev 2014 6;2014(11):CD010208. https://doi.org/10.1002/14651858.CD010208.pub2
42. Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: Systematic review and meta-analysis. Rheumatology 2020;59(Suppl_4):iv47-iv57. https://doi.org/10.1093/rheumatology/keaa246
43. Bodur H. Cardiovascular comorbidities in spondyloarthritis. Clin Rheumatol 2022:1-10. https://doi. org/10.1007/s10067-022-06473-9
44. Moltó A, Etcheto A, van der Heijde D, et  al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study. Ann Rheumat Dis 2016;75(6):1016-1023. https://doi.org/10.1136/annrheumdis-2015-208174
45. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: Results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheumat Dis 2014;73(1):243-246. https://doi.org/10.1136/annrheumdis-2012-203055
46. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal antiinflammatory drugs: A clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008;103(11):2908-2918. https://doi.org/10.1111/j.1572- 0241.2008.02200.x
47. Sieper J, Lenaerts J, Wollenhaupt J, et  al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: Results from the doubleblind, placebo-controlled INFAST study, Part 1. Ann Rheumat Dis 2014;73(1):101-107. https://doi. org/10.1136/annrheumdis-2012-203201
48. Wanders A, Heijde Dvd, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomised clinical trial. Arthr Rheumatism 2005;52(6):1756-1765. https://doi.org/10.1002/art.21054
49. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheumat Dis 2012;71(10):1623-1629. https://doi.org/10.1136/annrheumdis-2012-201370
50. Hintenberger R, Affenzeller B, Vladychuk V, Pieringer H. Cardiovascular risk in axial spondyloarthritis  – a systematic review. Clin Rheumatol 2023;42(10):2621-2633. https://doi. org/10.1007/s10067-023-06655-z
51. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013;(2):CD004524. https://doi.org/10.1002/14651858.CD004524.pub4
52. Haibel H, Brandt H, Song I, et  al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial. Ann Rheumatic Dis 2007;66(3):419-421. https://doi.org/10.1136/ ard.2006.054098
53. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014;2014(11):CD004800. https://doi.org/10.1002/14651858.CD004800.pub3
54. Wang R, Dasgupta A, Ward MM. Comparative efficacy of tumor necrosis factor-α inhibitors in ankylosing spondylitis: A systematic review and Bayesian network metaanalysis. J Rheumatol 2018;45(4):481-490. https://doi.org/10.3899/jrheum.170224
55. Hueber W, Sands BE, Lewitzky S, et  al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: Unexpected results of a randomised, double-blind placebocontrolled trial. Gut 2012;61(12):1693-1700. https://doi.org/10.1136/gutjnl-2011-301668
56. Yates M, Hamilton LE, Elender F, et  al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomised control trial. J Rheumatol 2015;42(7):1177-1185. https://doi.org/10.3899/jrheum.141335
57. Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: A randomised, prospective, long-term, followup study. Biologics 2013;7:1-6. https://doi.org/10.2147/BTT.S31474
58. Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long‐term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non–radiographically evident axial spondyloarthritis who experience a flare. Arthr Rheumatism 2013;65(8):2211-2213. https://doi.org/10.1002/art.38014
59. Richards C, Leslie WD. Trabecular bone score in rheumatic disease. Curr Rheumatol Rep 2022;24(4):81-87. https://doi.org/10.1007/s11926-022-01062-w
60. Westerveld L, Verlaan J, Oner F. Spinal fractures in patients with ankylosing spinal disorders: A  systematic review of the literature on treatment, neurological status and complications. Eur Spine J 2009;18(2):145-156. https://doi.org/10.1007/s00586-008-0764-0

Click here to access the pdf.